Drug transport by breast cancer resistance protein

ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin

(2010) B Tomlinson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

The Human Breast Cancer Resistance Protein (BCRP/ABCG2) Shows Conformational Changes with Mitoxantrone

(2010) Mark F. Rosenberg et al.   STRUCTURE

Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2)

(2009) Yash A. Gandhi et al.   AAPS Journal

Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia

(2009) Biren Saraiya et al.   ANTI-CANCER DRUGS

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients

(2009) Kimie Sai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA

(2009) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

ABCG2: the key to chemoresistance in cancer stem cells?

(2009) Yi An et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

(2009) Nielka P. van Erp et al.   JOURNAL OF CLINICAL ONCOLOGY

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

(2009) Pei-Chieng Cha et al.   JOURNAL OF HUMAN GENETICS

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

(2009) Kimberly K. Adkison et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death

(2009) Maria A.A. Cortez et al.   PEDIATRIC BLOOD & CANCER

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

(2009) S. G. Aller et al.   SCIENCE

Binding site of ABC transporter homology models confirmed by ABCB1 crystal structure

(2009) Aina W Ravna et al.   Theoretical Biology and Medical Modelling

Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations

(2009) Melanie Kolz et al.   PLoS Genetics

QSAR analysis and molecular modeling of ABCG2-specific inhibitors

(2008) E. Nicolle et al.   ADVANCED DRUG DELIVERY REVIEWS

Purification and structural analyses of ABCG2

(2008) Christopher A. McDevitt et al.   ADVANCED DRUG DELIVERY REVIEWS

Structure–activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)

(2008) Anne Pick et al.   BIOORGANIC & MEDICINAL CHEMISTRY

TheABCG2C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects

(2008) Kimberly K. Adkison et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE

The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies

(2008) SU Yasuda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

(2008) Y Yamasaki et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design

(2008) N. Giri et al.   DRUG METABOLISM AND DISPOSITION

Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone

(2008) J. S. Lagas et al.   DRUG METABOLISM AND DISPOSITION

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Homology modeling of breast cancer resistance protein (ABCG2)

(2008) Eszter Hazai et al.   JOURNAL OF STRUCTURAL BIOLOGY

Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study

(2008) Abbas Dehghan et al.   LANCET

Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters

(2008) M. Okabe et al.   MOLECULAR CANCER THERAPEUTICS

ATP-binding cassette transporters in human heart failure

(2008) Thomas F. Solbach et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

(2008) Bradley L. Urquhart et al.   Pharmacogenetics and Genomics

Pharmacogenomic importance of ABCG2

(2008) George Cusatis et al.   PHARMACOGENOMICS

Electrostatic funneling of substrate in mitochondrial inner membrane carriers

(2008) Y. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA